What is the cheapest insurance program a pre-seed biotech startup needs to operate legally?

A pre-seed biotech with no employees and no active clinical work can operate on a very minimal program: commercial general liability ($1M occurrence / $2M aggregate), workers compensation (statutory in every state once you have a single W-2 employee), and a modest D&O policy ($1M-$3M). Total annual premium for this floor program typically runs $4,000-$8,000.

The cost ramps materially once any of three things happen: institutional capital comes in, clinical activity starts, or PHI/biospecimen handling begins. Each of those events typically triples or quadruples the program cost — so the "cheap" period is the gap between formation and any of those triggers.

Workers compensation is statutory in every US state once you have a W-2 employee — the threshold and exact rules vary (in Texas, WC is technically optional but non-subscriber liability exposure makes operating without it impractical for any company with outside investors).

Commercial general liability is not statutorily required at the federal level but is universally required by commercial landlords (any office or wet lab lease), by professional service contracts (legal, accounting), and increasingly by SaaS vendors handling business data.

D&O is not statutorily required but is universally required by institutional investors — every priced round will include a D&O requirement in the closing conditions. Founders typically bind D&O at term sheet even before the first close.

Cyber liability — defer until you handle protected health information, biospecimens, or trial PHI. Pre-clinical biotech without any patient-facing infrastructure can defer cyber until clinical activity begins.

Professional liability (E&O) — defer until you sign service contracts that include professional liability requirements (most do not for pre-seed biotech).

Clinical trial liability — defer until you have an active or imminent clinical trial. Sponsor-side clinical trial liability is purchased per-trial; pre-clinical operators do not need it.

Products liability — defer until you have a commercial product or are within ~12 months of commercial launch. Pre-clinical and clinical-stage biotechs do not carry meaningful products liability towers.

Property — defer until you have meaningful physical infrastructure (wet lab equipment, biologic inventory, clinical trial material in-house). Pre-seed biotechs working out of incubator space typically have minimal property exposure beyond what the incubator carries.

D&O is the only insurance investors universally require at term sheet — typically $1M-$5M for seed-stage, $5M-$15M for Series A, scaling with round size. The investor side requires D&O to protect the board seats they're taking.

Some investors require employment practices liability insurance (EPLI) once headcount reaches 5-10 employees; this is sometimes included as a sub-limit on the D&O policy or written as a standalone $1M-$3M policy.

Fiduciary liability is sometimes required when the company sponsors a 401(k) plan or has employee benefit plans subject to ERISA; this is typically a $1M sub-limit on the D&O policy.

Texas allows non-subscriber operation for workers compensation, but operating as a non-subscriber means losing the exclusive-remedy defense — Texas non-subscriber employees can sue the company directly for any work-related injury with no caps. Any biotech with outside investors should subscribe to TX workers comp regardless of the size discount.

The Texas Medical Records Privacy Act (HB 300, Texas Health & Safety Code Ch. 181) imposes HIPAA-equivalent obligations on a broader set of entities than the federal definition. Texas biotech operators handling any patient or research-subject health data should evaluate cyber liability for HB 300 coverage even if HIPAA doesn't technically apply.